title: Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
abstract: We determined systemic oxidative stress in Parkinson's disease (PD) patients, patients with other neurological diseases (OND) and healthy controls by measurement of in vitro lipoprotein oxidation and levels of hydro- and lipophilic antioxidants in plasma and cerebrospinal fluid (CSF). Additionally, we investigated the influence of levodopa (LD) and dopamine agonist therapy (DA) on the oxidative status in PD patients. We found increased oxidative stress, seen as higher levels of lipoprotein oxidation in plasma and CSF, decrease of plasma levels of protein sulfhydryl (SH) groups and lower CSF levels of alpha-tocopherol in PD patients compared to OND patients and controls. Levodopa treatment did not significantly change the plasma lipoprotein oxidation but LD monotherapy tended to result in an increase of autooxidation and in a decrease of plasma antioxidants with significance for ubiquinol-10. DA monotherapy was significantly associated with higher alpha-tocopherol levels. Patients with DA monotherapy or co-medication with DA showed a trend to lower lipoprotein oxidation. These data support the concept of oxidative stress as a factor in the pathogenesis of PD and might be an indicator of a potential prooxidative role of LD and a possible antioxidative effect of DA in PD treatment.
authors.affiliation: Neurological Department, University Clinic Hamburg-Eppendorf, D-20246 Hamburg, Germany. buhmann@uke.uni-hamburg.de
authors.forename: Carsten
authors.initials: C
authors.lastname: Buhmann
authors.forename: Sönke
authors.initials: S
authors.lastname: Arlt
authors.forename: Anatol
authors.initials: A
authors.lastname: Kontush
authors.forename: Tobias
authors.initials: T
authors.lastname: Möller-Bertram
authors.forename: Sinje
authors.initials: S
authors.lastname: Sperber
authors.forename: Matthias
authors.initials: M
authors.lastname: Oechsner
authors.forename: Hans Joerg
authors.initials: HJ
authors.lastname: Stuerenburg
authors.forename: Ulrike
authors.initials: U
authors.lastname: Beisiegel
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000378:metabolism; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D010300:Parkinson Disease / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012016:Reference Values; D013438:Sulfhydryl Compounds / Q000097:blood; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D024502:alpha-Tocopherol / Q000134:cerebrospinal fluid
chemical_list: D000975:Antioxidants; D000978:Antiparkinson Agents; D015415:Biomarkers; D008074:Lipoproteins; D013438:Sulfhydryl Compounds; D014451:Ubiquinone; D007980:Levodopa; D024502:alpha-Tocopherol; C003741:ubiquinol; D001205:Ascorbic Acid; D004298:Dopamine